The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage - PubMed (original) (raw)
The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage
A H Elmaagacli et al. Ann Hematol. 2000 Aug.
Abstract
The use of the real-time reverse-transcription polymerase-chain reaction (RT-PCR) method to quantify BCR-ABL transcripts before and after allogeneic transplant was prospectively studied in 65 patients with chronic myeloid leukemia (CML). The expression of the BCR-ABL transcript was determined and normalized using the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeeping gene product as an endogenous reference. In the single step real-time PCR assay, tenfold serial dilutions of cDNA of the K5652 cell line remained positive down to 100 pg cDNA only. However, molecular relapses of CML after transplant were only safely detectable when a nested real-time PCR assay was performed, which was able to detect 1-10 pg cDNA from a tenfold serial dilution. The median normalized BCR-ABL transcript level was measured as 0.004% in 17 patients with a molecular relapse, 0.4% in 7 patients with a cytogenetic relapse, 2.6% in 36 patients with a stable phase of CML, and 36% in 5 patients with a relapse in a blast crisis. The analyzed median normalized amount of BCR-ABL transcript differed significantly (P<0.001) between the various disease stages. In ten CML patients with relapse, the real-time PCR method was used to monitor the response of various immunotherapies as donor leukocyte infusions, withdrawal of immunosuppression, or interferon-alpha application. The results of the quantitative evaluation of BCR-ABL transcripts reflected very well the clinical effect of the different applied immunotherapies. The new real-time PCR method seems to be a suitable technique for the early detection of relapse after allogeneic transplant in patients with the BCR-ABL transcript. Its ability to distinguish between molecular and cytogenetic relapse (P<0.001) allows early therapeutic decisions.
Similar articles
- Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay.
Preudhomme C, Révillion F, Merlat A, Hornez L, Roumier C, Duflos-Grardel N, Jouet JP, Cosson A, Peyrat JP, Fenaux P. Preudhomme C, et al. Leukemia. 1999 Jun;13(6):957-64. doi: 10.1038/sj.leu.2401426. Leukemia. 1999. PMID: 10360386 - Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature.
Ichinohasama R, Miura I, Takahashi N, Sugawara T, Tamate E, Endoh K, Endoh F, Naganuma H, DeCoteau JF, Griffin JD, Kadin ME, Ooya K. Ichinohasama R, et al. Leukemia. 2000 Jan;14(1):169-82. doi: 10.1038/sj.leu.2401606. Leukemia. 2000. PMID: 10637493 Review. - Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J, Alvarez MA, Torres A. Román J, et al. Haematologica. 2000 Oct;85(10):1072-82. Haematologica. 2000. PMID: 11025600 Review.
Cited by
- A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci G, Perrotti D. Notari M, et al. Blood. 2006 Mar 15;107(6):2507-16. doi: 10.1182/blood-2005-09-3732. Epub 2005 Nov 17. Blood. 2006. PMID: 16293596 Free PMC article. - Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring.
Bagg A. Bagg A. J Mol Diagn. 2002 Feb;4(1):1-10. doi: 10.1016/S1525-1578(10)60675-7. J Mol Diagn. 2002. PMID: 11826183 Free PMC article. Review. No abstract available. - Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
Osman AEG, Deininger MW. Osman AEG, et al. Blood Rev. 2021 Sep;49:100825. doi: 10.1016/j.blre.2021.100825. Epub 2021 Mar 16. Blood Rev. 2021. PMID: 33773846 Free PMC article. Review. - ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.
Perrotti D, Neviani P. Perrotti D, et al. Br J Cancer. 2006 Oct 9;95(7):775-81. doi: 10.1038/sj.bjc.6603317. Epub 2006 Sep 5. Br J Cancer. 2006. PMID: 16953242 Free PMC article. Review. - Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.
Thomas EK, Cancelas JA, Zheng Y, Williams DA. Thomas EK, et al. Leukemia. 2008 May;22(5):898-904. doi: 10.1038/leu.2008.71. Epub 2008 Mar 20. Leukemia. 2008. PMID: 18354486 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous